Gene targeting: Roadmap to future therapies Lars C. HuberThomas PapSteffen Gay Invited Commentary Pages: 323 - 325
Etanercept and methotrexate combination in rheumatoid arthritis Larry Moreland Clinical Trials Report Pages: 333 - 333
Targeting cytokines beyond tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis Iain B. McInnesJ. Alastair Gracie OriginalPaper Pages: 336 - 342
Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: Possible interactions and implications for treatment of rheumatoid arthritis Tobias KurthCharles H. HennekensJ. Michael Gaziano OriginalPaper Pages: 351 - 356
B cells: New ways to inhibit their function in rheumatoid arthritis Robert H. Carter OriginalPaper Pages: 357 - 363
Occupational and environmental exposures as risk factors for systemic lupus erythematosus Glinda S. CooperChristine G. Parks OriginalPaper Pages: 367 - 374
New advances in measurement of complement activation: Lessons of systemic lupus erythematosus Chau-Ching LiuSusan ManziJoseph M. Ahearn OriginalPaper Pages: 375 - 381
Biomarkers in systemic lupus erythematosus Gabor G. IlleiPeter E. Lipsky OriginalPaper Pages: 382 - 390